Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. The antibody was isolated from patient’s B-cells using state of the art molecular genomic techniques. “GT103”, the company’s lead asset, is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients.
Looking for a particular Grid Therapeutics employee's phone or email?
Grid Therapeutics Questions
The Grid Therapeutics annual revenue was $5 million in 2026.
Thomas Patz is the Chief Operating Officer and General Counsel of Grid Therapeutics.
2 people are employed at Grid Therapeutics.
Grid Therapeutics is based in Durham, North Carolina.
The NAICS codes for Grid Therapeutics are [5417, 541714, 54171, 54, 541].
The SIC codes for Grid Therapeutics are [873, 87].
Top Grid Therapeutics Employees
-
24
-
Ryan Dackor
Director, Clinical Operations at Grid Therapeutics
Charleston, SC, US33
Related Companies
